Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00420134
Status:
COMPLETED
Last Update Posted:
2009-09-17
First Post:
2007-01-08
Brief Title:
Improvement of Liver Function in Liver Cirrhosis Patients After Autologous Mesenchymal Stem Cell Injectiona Phase I-II Clinical Trial
Sponsor:
Shahid Beheshti University of Medical Sciences
Organization:
Shahid Beheshti University of Medical Sciences
Study Overview
Official Title:
A Phase OneTwo Clinical Trial on the Use of Autograft Mesenchymal Stem Cells Differentiated Into Progenitor of Hepatocytes for the Salvage Treatment of Patients With End-stage Liver Disease
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The methods for separation of mesenchymal stem cell were established in 2001 These cells can differentiate to osteocytes hepatocytes chondrocytes myocytes and etc In this study the investigators try to separate mesenchymal stem cell from end stage liver disease then these cells will be differentiated to progenitor of hepatocytes finally the investigators injected these cells into portal vein under ultrasound guide The investigators determine the effects of injected cells in reestablishment of liver function
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None